targeted binding agent, antibody, composition, isolated cell line isolated nucleic acid molecule, vector, host cell, methods for making a targeted binding agent, for isolating an antibody or antigen binding portion thereof, for making an antibody human monoclonal construct, to treat, prevent or alleviate the symptoms of a disorder, to inhibit the proliferation of a cancer cell, to inhibit an erbb2 activity in an erbb2 expressing cell, and to modulate an erbb2 activity in an erbb2 expressing cell. and non-human transgenic animal or transgenic plant

摘要

TARGET BINDING AGENT, ANTIBODY, COMPOSITION, ISOLATED CELL LINE, INSULATED NUCLEIC ACID MOLECLE, VECTOR, HOSPITAL DYNAMIC BODY ANOLYGER FOR METHODS HUMAN MONOCLONAL ANTIBODY, TO TREAT, PREVENT OR RELIEF SYMPTOMS OF A DISORDER, TO INHIBIT THE PROLIFERATION OF A CANCER CELL, TO INHIBIT AN ERBB2 ACTIVITY IN A CELL THAT EXPRESSES ERBB2, AND FOR EXPRESSING A CULB 2, AND ERBB2, E, NON-HUMAN TRANSGENIC ANIMAL OR TRANSGENIC PLANT. The present invention relates to antibodies including human antibodies and antigen binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized single chain antibodies, or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using antibodies and compositions for diagnosis and treatment. The invention also provides methods of gene therapy using nucleic acid molecules encoding heavy and / or light chain immunoglobulin molecules comprising human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising the nucleic acid molecules of the present invention.